our Premium Content: News alerts, weekly reports and conference planners

DRUG:

ONT-10

News alerts, weekly reports and conference planners

Company:

Pfizer

Drug class:

Immunostimulant, MUC1 inhibitor, TLR agonist

Related drugs:

falimarev/inalimarev (0)

Undisclosed MUC1 peptide-poly-ICLC adjuvant vaccine (0)

activated CIK and bispecific antibody (0)

activated CIK-anti-CD3/MUC1/CEA/EpCAM/GPC3 antibody (0)

tirvalimogene teraplasmid (2)

Histone H3.3-K27M Neoantigen Vaccine Therapy (1)

AdHER2/neu DC Vaccine (0)

bioengineered allogeneic immune cells (0)

velimogene aliplasmid (0)

interferon alpha 2b (0)

dasiprotimut-T (0)

Bria-OTS (0)

CD25hi Treg depleted DLI (0)

recombinant human papillomavirus bivalent vaccine (0)

CodaLytic (0)

dendritic cell vaccine (0)

cancer vaccine MUC-1 (0)

autologous dendritic cell vaccine leaded with autologous tumor cell lysate (0)

DI Leu16 IL-2 (0)

DNAJB1-PRKACA peptide vaccine (0)

Dendritic cell renal cell carcinoma fusion vaccine (0)

FR Alpha Peptide Vaccine (0)

GVAX leukemia vaccine (0)

GVAX lung cancer vaccine (0)

types 6, 11, 16, 18 (0)

human papillomavirus 9-valent vaccine, recombinant (0)

H1299 cell lysate with iscomatrix adjuvant vaccine (0)

H1299 lung cancer cell lysate vaccine with Montanide ISA-51 VG adjuvant (0)

HER-2 pulsed DC1 (0)

HER2- and HER3-primed dendritic cells (0)

IDH1R132H peptide vaccine (0)

autologous γδ T lymphocytes (0)

MMP9FS (0)

KRAS peptide vaccine (0)

axalimogene filolisbac (0)

MVA-BN-Brachyury IV vaccine (0)

MVI-816 (0)

autologous dendritic cell vaccine (0)

NY-ESO-1 Iscomatrix (0)

NY-ESO-1 combined with MPLA vaccine (0)

Poly-ICLC matured DC adjuvanted NY-ESO-1/Melan-A-MART-1 peptide vaccine (0)

PolyPEPI 1018 (0)

rilimogene galvacirepvec (0)

live attenuated bacillus Calmette-Guerin (0)

Tri-Ad5 (0)

CMV-MVA vaccine (0)

UV1 (0)

Undisclosed VLP vaccine (0)

Undisclosed ovarian cancer vaccine (0)

alpha-tocopheroloxyacetic acid (0)

allogeneic K562-GM tumor cell vaccine (0)

allogeneic Myeloma GM-CSF Vaccine (0)

alpha-lactalbumin vaccine (0)

PG2 (0)

autologous Tcm cellular immunotherapy (0)

autologous formalin-fixed tumor vaccine (0)

mammaglobin-A DNA vaccine (0)

TG4010 (0)

STAT-401 (0)

multi-epitope melanoma peptide (0)

neoantigen DNA vaccine (0)

neoantigen peptide vaccine (0)

nonavalent HPV vaccine (0)

ADU-741 (0)

oral therapeutic vaccine V3-X (0)

p.DOM-WT1-126 DNA vaccine (0)

pING-hHER3FL (0)

polyvalent vaccine-KLH conjugate (0)

CDX-1401 (0)

CMN-001 (0)

self-amplifying RNA cancer vaccine (0)

falimarev/inalimarev (0)

Undisclosed MUC1 peptide-poly-ICLC adjuvant vaccine (0)

activated CIK and bispecific antibody (0)

activated CIK-anti-CD3/MUC1/CEA/EpCAM/GPC3 antibody (0)

DPV-001 (0)

EIK1001 (0)

›

Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer (NCT02270372)

Phase 1b

Cascadian Therapeutics Inc.

Completed

Phase 1b

Cascadian Therapeutics Inc.

Completed

Last update posted :

05/17/2018

Initiation :

11/01/2014

Primary completion :

06/01/2016

Completion :

06/01/2016

MUC1

varlilumab (CDX 1127) • ONT-10

ONT-10

Trials

Trials